Australia

Bionomics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Agilex Biolabs Congratulates Bionomics Limited on BNC210 PK Results

Lead Product(s): BNC210

Therapeutic Area: Psychiatry/Psychology Product Name: BNC210

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 30, 2021

Details:

The 7-day dosing PK study in ten healthy volunteers demonstrated that at a dose of 900 mg given twice daily, the tablet formulation of BNC210 had steady-state 12-hourly exposure levels ranging from 33-57 mg.h/L. The trial met its primary endpoint.

Bionomics

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

Australia

Post An Enquiry

Virtual Booth

Virtual Innovation Day

Participation Not Confirmed

Update your events

Bionomics Successfully Completes A$22.9 million Equity Raise

Lead Product(s): BNC210

Therapeutic Area: Psychiatry/Psychology Product Name: BNC210

Highest Development Status: Phase II Product Type: Small molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: $22.9 million Upfront Cash: Undisclosed

Deal Type: Financing April 08, 2021

Details:

Bionomics' lead drug candidate BNC210, currently in development for initiation of a second Phase 2b trial for the treatment of PTSD, is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor.